FDA’s Project FrontRunner is transforming oncology drug development by promoting early-line evaluation of cancer therapies through flexible, efficient clinical trial designs. This initiative encourages incorporating FDA guidance into early-phase trials, accelerating access to promising treatments for patients. By fostering innovation and collaboration, Project FrontRunner supports precision medicine approaches, improves trial efficiency, and aims to bring effective oncology drugs to market faster, ultimately enhancing patient outcomes in cancer care.

Join for free to read